• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sublingual grass pollen immunotherapy not effective for moderate-severe seasonal allergic rhinitis

byAdarsh ManjunathandMichael Milligan
February 17, 2017
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. For patients with moderate to severe seasonal allergic rhinitis, 2 years of sublingual grass pollen immunotherapy was not significantly different than placebo at improving nasal response to allergen challenge at 3-year follow-up.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Allergic rhinitis has major effects on quality of life, sleep, and work and school performance. While antihistamines and topical nasal corticosteroids can be effective, many people do not respond sufficiently with these therapies. Grass pollen immunotherapy, both subcutaneous and sublingual, has emerged as an option that may alter the underlying course of the disease when given for 3 years. The purpose of this study was to determine whether only 2 years of sublingual immunotherapy could reduce symptoms after a nasal allergen challenge. A total of 106 adult patients at Imperial College of London with moderate to severe seasonal allergic rhinitis were randomized to 2 years of sublingual immunotherapy with placebo injections, subcutaneous immunotherapy with placebo tablets, or placebo injections and tablets. At 3 years after treatment initiation (1 year after treatment was discontinued), nasal allergen challenge was performed and total nasal symptoms scores (TNSS) were assessed, with 0 being the best score and 12 being the worst. The mean TNSS score for the sublingual immunotherapy group improved from 6.36 pretreatment to 4.73 at 3 years, whereas the placebo group’s score improved from 6.06 pretreatment to 4.81 at 3 years. The between-group difference was not significant.

Overall, this study suggests that for patients with moderate to severe seasonal allergic rhinitis, sublingual immunotherapy given for 2 years may not be effective at reducing symptoms. However, this study was not designed to compare 2 vs. 3 years of sublingual immunotherapy or sublingual vs. subcutaneous immunotherapy.

Click to read the study, published in JAMA

Relevant Reading: Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy

In-Depth [randomized controlled trial]: This was a randomized, double-blind, placebo-controlled single-center trial conducted from 2011-2015. The study enrolled 106 adult patients with a minimum 2-year clinical history of moderate to severe seasonal allergic rhinitis. Patients were randomized to 2 years of sublingual immunotherapy (daily tablets containing major allergen Phleum p 5) with monthly placebo injections, subcutaneous immunotherapy (monthly injections with Phleum p 5) with daily placebo tablets, or matched double placebo (both injections and tablets). The nasal allergen challenge was performed and TNSS scores were obtained before treatment, at 1 and 2 years of treatment, and at 3 years (1 year after treatment was discontinued). The primary outcome was TNSS comparing sublingual immunotherapy vs. placebo at 3 years with subcutaneous immunotherapy as the positive control.

RELATED REPORTS

Early peanut introduction was not associated with lower prevalence of peanut allergy

Early exposure to allergenic foods may reduce incidence of long-term food allergy

#VisualAbstract: Peanut oral immunotherapy desensitizes young children with non-anaphylactic peanut allergies

The study was not powered to compare sublingual vs. subcutaneous immunotherapy. The mean TNSS score for the sublingual immunotherapy group improved from 6.36 pretreatment (CI95% 5.76-6.96) to 4.73 (CI95% 3.97-5.48) at 3 years, whereas the placebo group’s score improved from 6.06 pretreatment (CI95% 5.23-6.88) to 4.81 (CI95% 3.97-5.65) at 3 years. The between-group difference, adjusted for baseline, was -0.18 (CI95% -1.25 to 0.90, p = 0.75), which was not significant. No serious treatment-related adverse events were recorded.

 

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: allergy
Previous Post

Scalp cooling reduces alopecia among women undergoing chemotherapy for breast cancer

Next Post

Augmented adoptive cell transfer eradicates solid tumors [PreClinical]

RelatedReports

Peanut allergy effectively treated with oral immunotherapy: the PALISADE trial
Gastroenterology

Early peanut introduction was not associated with lower prevalence of peanut allergy

August 9, 2022
Peripregnancy nut consumption may decrease development of nut allergies
Chronic Disease

Early exposure to allergenic foods may reduce incidence of long-term food allergy

July 5, 2022
#VisualAbstract: Endotracheal intubation offers no benefit over supraglottic airway in patients with out-of-hospital return of spontaneous circulation
StudyGraphics

#VisualAbstract: Peanut oral immunotherapy desensitizes young children with non-anaphylactic peanut allergies

April 13, 2022
Peanut allergy effectively treated with oral immunotherapy: the PALISADE trial
Emergency

Halloween and Easter associated with increased rates of anaphylaxis in Canadian pediatric patients

October 7, 2020
Next Post

Augmented adoptive cell transfer eradicates solid tumors [PreClinical]

Risk factors identified for adverse pregnancy outcomes in patients with stable lupus

AAP supports public health interventions for opioid-dependent pregnant women

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Children with mothers prescribed opioids more likely to overdose

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Same appointment mammogram results may result in less stress for patients being screened for breast cancer
  • Increased use of pediatric CT poses significant oncogenic risk [Classics Series]
  • Pediatric asthma morbidity is associated with geographic location and social determinants of health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.